Skip to main content

Greenlight Re Announces Financial Results for Third Quarter and Nine Months Ended September 30, 2025

Achieves Record Quarterly Underwriting Income, Leading to a Combined Ratio of 86.6% GRAND CAYMAN, Cayman Islands, Nov. 03, 2025 (GLOBE NEWSWIRE) — Greenlight Capital Re, Ltd. (NASDAQ: GLRE) (“Greenlight Re” or the “Company”) today reported its financial results for the third quarter and nine months ended September 30, 2025. Third Quarter 2025 Highlights (all comparisons are to third quarter 2024 unless noted otherwise):Gross premiums written increased 9.5% to $184.4 million; Net premiums earned increased 8.9% to $165.4 million; Net underwriting income of $22.3 million, compared to $6.1 million; Combined ratio of 86.6%, compared to 95.9%; Total investment loss of $17.4 million, compared to total investment income of $30.3 million; Net loss of $4.4 million, or -$0.13 per diluted ordinary share, compared to $35.2 million, or $1.01...

Continue reading

Ryman Hospitality Properties, Inc. Reports Third Quarter 2025 Results

NASHVILLE, Tenn., Nov. 03, 2025 (GLOBE NEWSWIRE) — Ryman Hospitality Properties, Inc. (NYSE: RHP), a leading lodging real estate investment trust (“REIT”) specializing in group-oriented, destination hotel assets in urban and resort markets, today reported financial results for the three and nine months ended September 30, 2025. Third Quarter 2025 Highlights and Recent Developments:The Company reported consolidated revenue of $592.5 million, driven by Hospitality segment revenue of $500.9 million and Entertainment segment revenue of $91.6 million. Generated consolidated net income of $34.0 million and consolidated Adjusted EBITDAre of $173.1 million. Booked over 667,000 same-store Hospitality(1) Gross Definite Room Nights for all future periods, at an all-time quarterly record estimated average daily rate (ADR) of $291. The JW...

Continue reading

COMSTOCK RESOURCES, INC. REPORTS THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS

FRISCO, TX, Nov. 03, 2025 (GLOBE NEWSWIRE) — Comstock Resources, Inc. (“Comstock” or the “Company”) (NYSE; NYSE Texas: CRK) today reported financial and operating results for the quarter ended September 30, 2025. Highlights of 2025‘s Third QuarterHigher natural gas prices in the third quarter drove improved financial results in the quarter.Natural gas and oil sales, including realized hedging gains, were $335 million for the quarter. Operating cash flow was $190 million or $0.65 per diluted share. Adjusted EBITDAX for the quarter was $249 million. Adjusted net income was $28 million or $0.09 per diluted share for the quarter.Three Western Haynesville wells turned to sales in the third quarter.These wells had an average lateral length of 8,566 feet and an average per well initial production...

Continue reading

Upwork Reports Third Quarter 2025 Financial Results

Achieves record quarterly revenue of $201.7 million in Q3 2025 Generates GAAP net income of $29.3 million and record adjusted EBITDA of $59.6 million, resulting in 15% profit margin and all-time high 30% adjusted EBITDA margin Raises FY2025 revenue and adjusted EBITDA guidance PALO ALTO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) — Upwork Inc. (Nasdaq: UPWK), the world’s human and AI-powered work marketplace, today announced its financial results for the third quarter of 2025. “The third quarter marked the start of the next chapter for Upwork. As we build the world’s human and AI-powered work marketplace, we’re driving phenomenal user productivity and engagement, resulting in a return to positive GSV growth,” said Hayden Brown, president and CEO, Upwork Inc. “We are executing with speed and precision across our growth levers of AI,...

Continue reading

Bogota Financial Corp. Reports Results for the Three and Nine Months Ended September 30, 2025

TEANECK, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) — Bogota Financial Corp. (NASDAQ: BSBK) (the “Company”), the holding company for Bogota Savings Bank (the “Bank”), reported net income for the three months ended September 30, 2025 of $455,000, or $0.04 per basic and diluted share, compared to a net loss of $367,000, or $0.03 per basic and diluted share, for the comparable prior year period. The Company reported net income for the nine months ended September 30, 2025 of $1.4 million, or $0.11 per basic and diluted share, compared to a net loss of $1.2 million, or $0.10 per basic and diluted share, for the comparable prior year period. Income for the nine months ended September 30, 2025 included a one-time death benefit from a bank-owned life insurance policy related to a former employee of approximately $543,000. On August 12, 2025,...

Continue reading

UFP Technologies Announces Strong Q3 2025 Results

NEWBURYPORT, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) — UFP Technologies, Inc. (Nasdaq: UFPT), a contract development and manufacturing organization that specializes in single-use and single-patient medical devices, today reported net income of $16.4 million or $2.11 per diluted common share outstanding for its third quarter ended September 30, 2025, the same as in Q3 of 2024. Adjusted earnings per diluted share outstanding for the third quarter ended September 30, 2025, was $2.39. Sales for the third quarter were $154.6 million compared to sales of $145.2 million in the third quarter of 2024. Net income for the nine-month period ended September 30, 2025, was $50.7 million or $6.52 per diluted common share outstanding compared to net income of $42.6 million or $5.49 per diluted common share outstanding for the same period in 2024....

Continue reading

Castle Biosciences Reports Third Quarter 2025 Results

Delivered Q3 2025 revenue of $83 million Q3 2025 non-dermatologic revenue increased by 67% over Q3 2024 Q3 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 36% over Q3 2024 Raising full-year 2025 revenue guidance to $327-335 million from $310-320 million Announced launch of AdvanceAD-Tx™, the Company’s test designed to guide systemic treatment decision making in patients ages 12 and older with moderate-to-severe atopic dermatitis (AD) Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, Nov. 03, 2025 (GLOBE NEWSWIRE) — Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the third quarter and nine months ended Sept. 30, 2025. “We delivered a strong...

Continue reading

The Ensign Group Reports Third Quarter 2025 Results; Raises Annual Earnings and Revenue Guidance

Conference Call and Webcast scheduled for tomorrow, November 4, 2025 at 10:00 am PT SAN JUAN CAPISTRANO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) — The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign(TM) group of companies, which provide post-acute healthcare services and invest in the long-term healthcare industry, primarily in skilled nursing and senior living facilities, announced operating results for the third quarter of 2025, reporting GAAP diluted earnings per share of $1.42 and adjusted earnings per share(1) of $1.64, both for the quarter ended September 30, 2025. Highlights Include:GAAP diluted earnings per share for the quarter was $1.42, an increase of 6.0% over the prior year quarter, and adjusted diluted earnings per share(1) for the quarter was $1.64, an increase of 18.0% over the prior year quarter. GAAP...

Continue reading

Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution

HighlightsThird quarter 2025 revenue of $205.7 million decreased by 4% year-over-year but was flat when excluding previously discussed headwinds1 of $8.1 million, consistent with management expectations. Third quarter 2025 hereditary cancer testing revenue and volume grew 3% and 11% year-over-year, respectively. Third quarter 2025 gross margin was 69.9%. Third quarter 2025 GAAP net loss of $27.4 million, or $0.29 per share, while adjusted EPS was $0.00. Third quarter 2025 adjusted EBITDA was $10.3 million. Entered a strategic collaboration with SOPHiA GENETICS (Nasdaq: SOPH) to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) testing solution.SALT LAKE CITY, Nov. 03, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic...

Continue reading

EverQuote Announces Third Quarter 2025 Financial Results

Third Quarter Revenue Growth of 20% Year-Over-Year to $173.9 million Record Third Quarter Net Income up 63% Year-Over-Year to $18.9 million Record Adjusted EBITDA Increases 33% Year-Over-Year to $25.1 millionCAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) — EverQuote, Inc. (Nasdaq: EVER), a leading online insurance marketplace, today announced financial results for the third quarter ended September 30, 2025. “In the third quarter, we achieved record top and bottom line performance and we are making steady progress towards our vision of becoming the leading growth partner to P&C insurance providers,” said Jayme Mendal, CEO of EverQuote. “We are innovating new products, releasing features and further embedding AI into our marketplace to accelerate our transformation from a lead generation vendor to a multi-product, AI-powered...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.